TRVI - NASDAQ
Trevi Therapeutics, Inc.
$13.93
+3.6%Trevi Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of Haduvio to treat serious neurologically mediated conditions. The company is developing Haduvio, an oral extended-release formulation of nalbuphine, which is in phase IIb/III clinical trial for the treatment of chronic pruritus, chronic cough in patients with idiopathic pulmonary fibrosis. It has a license agreement with Endo Pharmaceuticals Inc. to develop and commercialize products incorporating nalbuphine hydrochloride in any formulation. The company was incorporated in 2011 and is headquartered in New Haven, Connecticut.
At a Glance
Live Snapshottrvi
Common Stock
Last Annual Value
128.00K
3-Year CAGR
29%
5-Year CAGR
46%
10-Year CAGR
41%
Trevi Therapeutics, Inc. Competitors Analysis of Common Stock
| Company | Common Stock | CAGR 3Y | CAGR 5Y | CAGR 10Y | |
|---|---|---|---|---|---|
Trevi Therapeutics, Inc. NASDAQ:TRVI | 128.00K | 23.5% | 34.6% | 41.4% | |
 Ardelyx, Inc. NASDAQ:ARDX | 24.00K | 1.4% | 13.0% | 17.0% | |
 Zenas BioPharma, Inc. NASDAQ:ZBIO | 5.00K | N/A | N/A | N/A | |
 ORIC Pharmaceuticals, Inc. NASDAQ:ORIC | 11.00K | 22.4% | 22.4% | N/A | |
 Novavax, Inc. NASDAQ:NVAX | 1.65M | 5.5% | 16.6% | -4.9% | |
 Precigen, Inc. NASDAQ:PGEN | 0.00 | N/A | N/A | N/A | |
 Tourmaline Bio, Inc. NASDAQ:TRML | 3.00K | 14.5% | -5.6% | N/A | |
 Terns Pharmaceuticals, Inc. NASDAQ:TERN | 11.00K | 22.4% | 29.7% | N/A | |
 Upstream Bio, Inc. NASDAQ:UPB | 53.00K | 160.4% | N/A | N/A |
Trevi Therapeutics, Inc. Fair Value Envelope
Related Guides
Continue your TRVI research with focused valuation guides.
Research Paths
Snapshot
Start with context, operating signals, and key market metrics.
Value Model
Stress test fair value across bear, base, and bull assumptions.
Statements
Validate revenue quality, margins, and balance sheet durability.
Earnings Call
Read management commentary and compare it with reported outcomes.
Dividends
Check payout sustainability and long-term distribution behavior.
Analyst Expectations
Review consensus spread and where estimate risk is concentrated.